Dimiou, Savvas;
Lopes, Rui M;
Kubajewska, Ilona;
Mellor, Ryan D;
Schlosser, Corinna S;
Shet, Manjunath S;
Huang, Hugh;
... Uchegbu, Ijeoma F; + view all
(2022)
Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure.
International Journal of Pharmaceutics
, 618
, Article 121658. 10.1016/j.ijpharm.2022.121658.
Preview |
Text
Accepted Manuscript Int J Pharm.pdf - Accepted Version Download (881kB) | Preview |
Abstract
Levodopa (L-DOPA) is an oral Parkinson's Disease drug that generates the active metabolite - dopamine (DA) in vivo. However, oral L-DOPA exhibits low oral bioavailability, limited brain uptake, peripheral DA-mediated side effects and its poor brain bioavailability can lead to long-term complications. Here we show that L-DOPA forms stable (for at least 5 months) 300 nm nanoparticles when encapsulated within N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ). A nano-in-microparticle GCPQ-L-DOPA formulation (D50 = 7.2 µm), prepared by spray-drying, was stable for one month when stored at room and refrigeration temperatures and was capable of producing the original GCPQ-L-DOPA nanoparticles upon aqueous reconstitution. Nasal administration of reconstituted GCPQ-L-DOPA nanoparticles to rats resulted in significantly higher DA levels in the brain (Cmax of 94 ng g-1 above baseline levels 2 h post-dosing) when compared to nasal administration of L-DOPA alone, with DA being undetectable in the brain with the latter. Furthermore, nasal GCPQ-L-DOPA resulted in higher levels of L-DOPA in the plasma (a 17-fold increase in the Cmax, when compared to L-DOPA alone) with DA undetectable in the plasma from both formulations. These data provide evidence of effective delivery of DA to the brain with the GCPQ-L-DOPA formulation.
Archive Staff Only
 |
View Item |
